Patent details

Basic Information

Publication number:

EP1282438

PCT Application Number:

PCT/DK/2001/000322

Type:

European Patent Granted for LU

Legal Status:

Lapsed

Application number:

EP019314582

PCT Publication Number:

WO/2001/085198

First applicant's nationality:

Translation Language:

EPO Publication Language:

English

English Title of Invention:

USE OF PHARMACEUTICAL COMPOSITION COMPRISING A FACTOR VIIA AND A FACTOR XIII

French Title of Invention:

UTILIASATION D'UNE COMPOSITION PHARMACEUTIQUE COMPRENANT UN FACTEUR VIIA ET UN FACTEUR XIII

German Title of Invention:

VERWENDUNG VON FAKTOR VII-A UND FAKTOR XIII ENTHALTENDEN PHARMAZEUTISCHEN VERBINDUNGEN

SPC Number:

Dates

Filing date:

10/05/2001

Grant date:

03/08/2005

EP Publication Date:

03/08/2005

PCT Publication Date:

15/11/2001

Claims Translation Received Date:

Translations Received Date (B1 EP Publication):

Translations Received Date (B2 EP Publication):

Translations Received Date (B3 EP Publication):

Publication date:

12/02/2003

EP B1 Publication Date:

03/08/2005

EP B2 Publication Date:

EP B3 Publication Date:

Lapsed date:

10/05/2006

Expiration date:

10/05/2021

Renunciation date:

Revocation date:

Annulment date:

Owner

From:

10/05/2001

 

 

Name:

Novo Nordisk Health Care AG

Address:

Andreasstrasse 15, 8050 Zürich, Switzerland (CH)

Inventor

1

Name:

ROJKJAER Rasmus

Address:

Denmark (DK)

2

Name:

PETERSEN Lars, Christian

Address:

Denmark (DK)

3

Name:

HEDNER Ulla

Address:

Sweden (SE)

Priority

1

Priority Number:

200000771

Priority Date:

10/05/2000

Priority Country:

Denmark (DK)

2

Priority Number:

200000778

Priority Date:

10/05/2000

Priority Country:

Denmark (DK)

3

Priority Number:

200000871

Priority Date:

06/06/2000

Priority Country:

Denmark (DK)

Classification

Main IPC Class:

A61K 38/36;

Filing date	Document type	Number of pages